FDA Clarifies NDA and ANDA Pathways for Nonprescription Drug Sponsors Entering OTC Market

Consumer behavior studies, not just clinical data, are the regulatory differentiator that determines whether an OTC drug application clears FDA review, and sponsors who underestimate that burden risk late-stage deficiencies. The agency's updated guidance on nonprescription drug application pathways makes the evidentiary expectations explicit for both NDA and ANDA submissions.

Two distinct routes exist for bringing a nonprescription drug to the U.S. market: the drug application process and the OTC monograph process. Under the drug application process, a sponsor must receive FDA approval of an NDA or ANDA before any commercial marketing can begin. Critically, a sponsor may submit directly for nonprescription status without prior prescription approval, or pursue an Rx-to-OTC switch for a product already approved under prescription labeling.

The evidentiary gap between a prescription NDA and a nonprescription NDA centers on consumer behavior studies. Because no healthcare provider supervises use in an OTC setting, FDA requires sponsors to demonstrate safe and effective self-use through a structured sequence of studies. Label comprehension studies come first, assessing whether consumers understand Drug Facts labeling and can apply it to hypothetical use decisions. Once the most effective label is established, self-selection studies evaluate whether consumers can accurately apply that labeling to their own health circumstances to decide appropriately on product use.

Actual use studies then move evaluation into real-world conditions, identifying use errors or self-diagnosis failures that controlled settings may not surface. Human factors studies close the sequence by examining the product's user interface design for use-related hazards, a requirement that aligns with broader human factors engineering expectations now embedded across device and combination product reviews. Sponsors should treat these four study types as interdependent, not interchangeable; sequencing errors or gaps in the label comprehension-to-self-selection handoff are a documented source of complete response letters.

FDA's Office of Nonprescription Drugs (for NDA products) and Office of Generic Drugs (for ANDA products) both encourage early engagement, specifically so sponsors can incorporate agency recommendations into preclinical and clinical development planning before commitments are made. Pre-submission meetings at the IND stage remain the most efficient mechanism for aligning on study design before resources are committed to protocols that may not satisfy the agency's evidentiary standard.

Sponsors targeting an NDA or ANDA filing date should treat the consumer behavior study sequence as a critical-path item, with label comprehension study completion gating the self-selection protocol initiation.

Source: FDA Office of Nonprescription Drugs via FDA.gov Drugs RSS Feed, May 21, 2026.